This site is intended for healthcare professionals only
The CMA has slapped more than £100 million worth of fines on Advanz Pharma, HgCapital and Cinven after it concluded that the price of a thyroid drug was inflated by 1,110%.
The outcome of a Competition and Markets Authority’s (CMA) investigation, published today (July 29), found that Advanz charged an excessive price for its liothyronine tablets, which are used to treat thyroid hormone deficiency.
Register to gain full access to C+D and C+D Community content
Already registered?
Already registered?
Due to shortages in coal tar scalp ointment, the DHSC has asked the manufacturer of an equivalent product - Sebco - to provide increased stock levels to support patients during this time.
Pharmacies in Scotland have been asked to ensure they have the “appropriate stock” of naloxone – a medicine used to reverse the effects of an opiate overdose – following an “increase in sudden collapse” due to overdoses.
As the dust settles on the announcement that NHS England (NHSE) is set for the scrapheap, questions on what a 50% headcount cut means for local commissioners remain…